These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37383088)

  • 1. A case report of a patient presented with skin ulcer after treatment of lenvatinib.
    Cha S; Kim DW; Choe JW; Kim TH; Kim SY; Hyun JJ; Jung SW; Koo JS; Jung YK; Yim HJ
    J Liver Cancer; 2021 Sep; 21(2):194-198. PubMed ID: 37383088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colitis induced by Lenvatinib in a patient with advanced hepatocellular carcinoma.
    Miyajima S; Tsuji K; Kito Y; Yoshida N; Matsunaga K; Tsuji S; Katayanagi K; Yonezawa M; Kubo A; Ushijima K; Minato H; Doyama H
    Clin J Gastroenterol; 2021 Feb; 14(1):187-192. PubMed ID: 33025343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion hepatectomy for hepatocellular carcinoma with main portal vein tumour thrombus after lenvatinib treatment: A case report.
    Takahashi K; Kim J; Takahashi A; Hashimoto S; Doi M; Furuya K; Hashimoto R; Owada Y; Ogawa K; Ohara Y; Akashi Y; Hisakura K; Enomoto T; Shimomura O; Noguchi M; Oda T
    World J Hepatol; 2021 Mar; 13(3):384-392. PubMed ID: 33815680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe skin ulcer caused by taking lenvatinib after proton beam therapy.
    Iwasa T; Adachi S; Ogiso H; Takada E; Mabuchi M; Suzuki Y; Yamauchi O; Saito K; Iwashita T; Ogino H; Shimizu M
    Clin J Gastroenterol; 2023 Aug; 16(4):588-592. PubMed ID: 37147555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenvatinib-induced tumor lysis syndrome in a patient with advanced hepatocellular carcinoma: a case report.
    Shimizu Y; Sunagozaka H; Yamagata K; Hirai H; Miura M; Yonemoto Y; Naito Y; Hasatani K; Yoshikawa J; Aoyagi H; Kaneko S
    Clin J Gastroenterol; 2021 Apr; 14(2):645-649. PubMed ID: 33389590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A rare case of unresectable, microsatellite instability-high hepatocellular carcinoma and an examination of the tumor microenvironment.
    Tomiyama T; Itoh S; Toshida K; Morinaga A; Fujimoto-Kosai Y; Tomino T; Kurihara T; Nagao Y; Morita K; Harada N; Kohashi K; Eguchi Y; Oda Y; Mori M; Yoshizumi T
    Int Cancer Conf J; 2023 Jan; 12(1):81-86. PubMed ID: 36605838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful hepatic resection for recurrent hepatocellular carcinoma after lenvatinib treatment: A case report.
    Yokoo H; Takahashi H; Hagiwara M; Iwata H; Imai K; Saito Y; Matsuno N; Furukawa H
    World J Hepatol; 2020 Dec; 12(12):1349-1357. PubMed ID: 33442460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction in Tumor Stain at 2 Weeks after Treatment Initiation Is a Predictor of the Efficacy of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma.
    Kunimoto H; Shakado S; Tanaka T; Takata K; Yamauchi R; Fukuda H; Tsuchiya N; Yokoyama K; Morihara D; Takeyama Y; Hirai F; Sakisaka S
    Oncology; 2020; 98(11):779-786. PubMed ID: 32877911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-PD-1 antibodies plus lenvatinib in patients with unresectable hepatocellular carcinoma who progressed on lenvatinib: a retrospective cohort study of real-world patients.
    Zou J; Huang P; Ge N; Xu X; Wang Y; Zhang L; Chen Y
    J Gastrointest Oncol; 2022 Aug; 13(4):1898-1906. PubMed ID: 36092355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rectal ulcer associated with lenvatinib 15 years after definitive radiotherapy for prostate cancer: A case report.
    Kawata Y; Watanabe K; Tokiya R; Miyaji Y; Shiotani A; Katsui K
    Oncol Lett; 2024 Jan; 27(1):6. PubMed ID: 38028175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study.
    Zhao L; Chang N; Shi L; Li F; Meng F; Xie X; Xu Z; Wang F
    Heliyon; 2022 Jun; 8(6):e09538. PubMed ID: 35706954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nephrotic Syndrome Induced by Lenvatinib Treatment for Hepatocellular Carcinoma.
    Prasoppokakorn T; Thanapirom K; Treeprasertsuk S
    Case Reports Hepatol; 2022; 2022():5101856. PubMed ID: 36106338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic encephalopathy induced by Lenvatinib and anti-PD-1 mAb in a patient with advanced hepatocellular carcinoma: A case report.
    Liu Z; Meng Y; Xiao W; Wang H; Sun L; Fu Z; Xiong X; Zhang S
    Mol Clin Oncol; 2021 Jun; 14(6):110. PubMed ID: 33859824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cotreatment with lenvatinib and warfarin potassium caused prothrombin time prolongation.
    Sasaki Y; Sakamori R; Yamada R; Shigekawa M; Tahata Y; Makino Y; Nakabori T; Kodama T; Hikita H; Tatsumi T; Takehara T
    Hepatol Res; 2019 Nov; 49(11):1357-1361. PubMed ID: 31119866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term management of recurrent papillary thyroid carcinoma treated with lenvatinib for over 5 years: a case report.
    Imai T; Kobayashi H; Senaha T; Imaizumi T; Murata Y
    Surg Case Rep; 2022 Jan; 8(1):21. PubMed ID: 35084585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the safety and prognosis of sequential regorafenib after sorafenib and lenvatinib treatment failure in patients with unresectable hepatocellular carcinoma: a retrospective cohort study.
    Zhai J; Liu J; Fu Z; Bai S; Li X; Qu Z; Sun Y; Ge R; Xue F
    J Gastrointest Oncol; 2022 Jun; 13(3):1278-1288. PubMed ID: 35837155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interstitial pneumonia suspected during regorafenib administration and exacerbated by subsequent therapy with lenvatinib for unresectable hepatocellular carcinoma.
    Kotani K; Enomoto M; Okada M; Yoshida K; Motoyama H; Fujii H; Hagihara A; Uchida-Kobayashi S; Morikawa H; Murakami Y; Tamori A; Kawada N
    Clin J Gastroenterol; 2019 Aug; 12(4):355-360. PubMed ID: 31020569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Destructive thyroiditis presenting as thyrotoxicosis followed by hypothyroidism during lenvatinib therapy for hepatocellular carcinoma.
    Suoh M; Fujii H; Nagata Y; Kotani K; Hagihara A; Enomoto M; Tamori A; Inaba M; Kawada N
    Clin J Gastroenterol; 2020 Oct; 13(5):860-866. PubMed ID: 32128670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion surgery for advanced hepatocellular carcinoma after combination treatment of lenvatinib and camrelizumab: a case report.
    Chen Z; Chen Z; Fan W; Zou Y; Zhang Y; Shi N; Jin H
    World J Surg Oncol; 2023 Jan; 21(1):29. PubMed ID: 36721173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Lenvatinib Therapy for Unresectable Hepatocellular Carcinoma in a Real-World Practice in Korea.
    Goh MJ; Oh JH; Park Y; Kim J; Kang W; Sinn DH; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Liver Cancer; 2021 Feb; 10(1):52-62. PubMed ID: 33708639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.